KKR, a prominent global investment firm, along with Impilo, a Nordic healthcare investment firm, has agreed to acquire Immedica Pharma, a Swedish-based pharmaceutical company specializing in rare diseases and specialty care products. As part of the deal, Impilo will reinvest to become an equal partner alongside KKR. The transaction is subject to customary regulatory approvals.
Together, KKR and Impilo will collaborate with Immedica’s management team to support its ongoing growth initiatives, including the launch of Loargys, an ultra-orphan drug recently approved. Additionally, the company plans to expand its pipeline, pursue in-licensing opportunities, and explore entry into the U.S. market pending regulatory approvals.
Established in 2018 by Impilo and a seasoned management team, Immedica has rapidly become a leader in the European rare disease space. With a portfolio focused on haematology, oncology, genetic, and metabolic diseases, Immedica has achieved annual revenue of EUR 100 million and a growth rate exceeding 50%. The company’s success is attributed to strategic acquisitions, in-licensing agreements, and the development of a robust commercialization network spanning Europe and the Middle East.
Kugan Sathiyanandarajah, Partner and Head of KKR’s Health Care Strategic Growth business in Europe, expressed confidence in Immedica’s potential and praised its management team’s accomplishments. Magnus Edlund, Partner at Impilo, highlighted KKR’s experience and global network as valuable assets for Immedica’s future growth.
Anders Edvell, CEO of Immedica, expressed excitement about the partnership with KKR and the continued collaboration with Impilo. He emphasized Immedica’s commitment to addressing unmet medical needs in the rare disease sector and looked forward to expanding the company’s global footprint.
KKR’s investment in Immedica is made through its KKR Health Care Strategic Growth Fund II, reflecting the firm’s dedication to high-growth healthcare companies. Impilo received financial advice from Morgan Stanley & Co. International, while KKR was advised by BofA Securities. Legal counsel was provided by Latham & Watkins for Impilo and Gibson Dunn for KKR, among others.
About KKR KKR is a leading global investment firm offering alternative asset management and capital markets solutions. With a focus on generating attractive investment returns and supporting growth in its portfolio companies, KKR has a long track record of success in the healthcare sector.
Through strategic partnerships and disciplined investment approaches, KKR aims to create value for its investors and communities worldwide.
